The aim of this study is to compare outcomes in Chinese patients with locally advanced resectable esophageal squamous cell cancer who have received either surgery or definitive chemoradiation (CRT) by the randomized, open-label, multicenter trial.
Chinese
esophageal squamous cell cancer
mid or lower esophageal cancer
tumor is resectable disease
who had distant metastasis to solid visceral organs or local invasion into trachea, descending aorta, or recurrent laryngeal nerve.
who had a serious premorbid condition or a poor physical status that compromised a thoracotomy.
The First Affiliated Hospital of Henan University of Science and Technology
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborator
Anyang Tumor Hospital
Collaborator
150th Hospital of PLA
Collaborator